Condition
Schizophrenia or Schizoaffective Disorder
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 4 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02504476Phase 1CompletedPrimary
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
NCT02567370Phase 1CompletedPrimary
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
NCT01016145Phase 4UnknownPrimary
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
Showing all 3 trials